As of November 1, 2020, we will discontinue future development for Internet Explorer

To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. Sorry for the convenience.

Powering Precision
A Blog

Date:

Biomarker Types and CDx Biomarkers

The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases. Within oncology where nearly all of…

Date:

Liquid Biopsies

Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy. Liquid biopsy has a broad…

Date:

TriCon 2021 Perspective

It was no surprise that Molecular Med Tri-Con 2021 was a virtual event this year. Not only was the format of the conference shaped by the global pandemic, the impact of COVID-19 on our industry as…

Date:

Why does IHC remain so popular for CDx development?

The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development. The discussion came up during our 2020 wrap up, looking at all active CDx or CDx-…

Date:

New China operation

December 30th was an exciting day for NeoGenomics as we got the keys to our new facility in Suzhou, China. Suzhou is about 60 miles from Shanghai and is the new home for PPD and NeoGenomics newest…

Date:

CRO and Clinical Reference Laboratory Commercial Incentives

One of the challenges developing a companion diagnostic is creating a test that runs well in both clinical trials, and following regulatory approval, clinical testing laboratories Unfortunately, in…

Date:

Oncology Clinical Trials During a Pandemic

2020 has really been a year that doesn’t quit, hasn’t it? The dangerous part of COVID-19 has been how rapidly it has overwhelmed our healthcare system, in particular, how it has affected cancer…

Date:

It’s a Great Clinical Trial Assay

Can it be commercialized?

Date:

Is It Validated?

NeoGenomics has a menu of >600 assays across many different technologies and approaches. Clients often approach us after searching our menu online and ask if we can “Provide Test X for Clinical…

Date:

Liquid Biopsy Testing for PIK3CA Mutation

For years, researchers have looked into liquid biopsy as a potentially useful tool to help Health Care Providers assess a patient’s response to treatment, monitor cancer recurrence and even detect…
Close Menu